Dividend Investing Ideas Center
Critical Facts You Need to Know About Preferred Stocks
Have you ever wished for the safety of bonds, but the return potential...
You take care of your investments. We like that.
Upgrade to Premium to access your Watchlist and more.
Global X China Biotech Innovation ETF
ETF
CHB
Payout Change
Pending
Price as of:
$6.64
+0.0
+0.0%
primary theme
N/A
CHB (ETF)
Global X China Biotech Innovation ETF
Payout Change
Pending
Price as of:
$6.64
+0.0
+0.0%
primary theme
N/A
CHB (ETF)
Global X China Biotech Innovation ETF
Payout Change
Pending
Price as of:
$6.64
+0.0
+0.0%
primary theme
N/A
Name
As of 02/23/2024Price
Aum/Mkt Cap
YIELD
Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.
Exp Ratio
Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.
Watchlist
Vitals
YTD Return
-18.0%
1 yr return
-30.3%
3 Yr Avg Return
-26.9%
5 Yr Avg Return
N/A
Net Assets
$2.05 M
Holdings in Top 10
61.0%
52 WEEK LOW AND HIGH
$6.6
$6.64
$10.04
Expenses
OPERATING FEES
Expense Ratio 0.65%
SALES FEES
Front Load N/A
Deferred Load N/A
TRADING FEES
Turnover N/A
Redemption Fee N/A
Min Investment
Standard (Taxable)
N/A
IRA
N/A
Fund Classification
Fund Type
Exchange Traded Fund
Name
As of 02/23/2024Price
Aum/Mkt Cap
YIELD
Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.
Exp Ratio
Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.
Watchlist
CHB - Profile
Distributions
- YTD Total Return -18.0%
- 3 Yr Annualized Total Return -26.9%
- 5 Yr Annualized Total Return N/A
- Capital Gain Distribution Frequency N/A
- Net Income Ratio -0.31%
- Dividend Yield 0.1%
- Dividend Distribution Frequency SemiAnnual
Fund Details
-
Legal NameGlobal X China Biotech Innovation ETF
-
Fund Family NameGlobal X Funds
-
Inception DateSep 22, 2020
-
Shares Outstanding270100
-
Share ClassN/A
-
CurrencyUSD
-
Domiciled CountryUS
-
ManagerNam To
Fund Description
The Fund invests at least 80% of its total assets, plus borrowings for investment purposes (if any), in the securities of the Solactive China Biotech Innovation Index ("Underlying Index") and in American Depositary Receipts ("ADRs") and Global Depositary Receipts ("GDRs") based on the securities in the Underlying Index. The Fund's 80% investment policy is non-fundamental and requires 60 days prior written notice to shareholders before it can be changed.
The Underlying Index is designed to provide exposure to exchange-listed companies that are directly involved in China’s biotechnology industry. The securities eligible for inclusion in the Underlying Index include:
•H-Shares (securities of companies incorporated in China that are denominated in Hong Kong Dollars and listed on the Hong Kong Stock Exchange (the "HKSE"));
•Red Chips (securities of companies with a majority of their business operations in mainland China and that are controlled by the national government or local governments of China, traded on the HKSE in Hong Kong dollars);
•P-Chips (securities of companies with the majority of their business operations in mainland China and controlled by individuals in China, but that are incorporated outside of China);
•A-Shares (securities of companies incorporated in mainland China that trade on Chinese exchanges in renminbi) that are accessible through the Shanghai-Hong Kong Stock Connect program ("Shanghai Connect") or the Shenzhen-Hong Kong Stock Connect program ("Shenzhen Connect", and together with Shanghai Connect, "Stock Connect Programs"); and
•Foreign listings such as American Depository Receipts ("ADRs").
The Stock Connect Programs are securities trading and clearing programs that aim to achieve mutual stock market access between China and Hong Kong. Under the Stock Connect Programs, the Fund's trading of eligible A-Shares listed on the Shanghai Stock Exchange ("SSE") or Shenzhen Stock Exchange ("SZSE"), as applicable, would be effectuated through its Hong Kong brokers. Trading through the Stock Connect Programs is subject to a daily quota, which limits the maximum net purchases under Stock Connect Programs each day, and as such, buy orders for A-Shares would be rejected once the daily quota is exceeded (although the Fund will be permitted to sell A-Shares regardless of the daily quota balance). The daily quota is not specific to the Fund. From time to time, other stock exchanges in China may participate in Stock Connect Programs, and A-Shares listed and traded on such other stock exchanges and accessible through Stock Connect Programs may be added to the Underlying Index, as determined by Solactive AG, the provider of the Underlying Index (the “Index Provider”).
In constructing the Underlying Index, the Index Provider utilizes FactSet Industry classifications to identify companies that are directly involved in the biotechnology industry. Only those securities classified in the biotechnology industry according to FactSet as of each rebalance date are eligible for inclusion in the Underlying Index.
To be a part of the eligible universe of the Underlying Index, certain minimum market capitalization and liquidity criteria, as defined by the Index Provider, must be met. As of January 31, 2023, companies must have a minimum free float market capitalization of $200 million and a minimum average daily turnover for the last 6 months greater than or equal to $2 million in order to be eligible for inclusion in the Underlying Index.
The Underlying Index is weighted according to a modified capitalization weighting methodology and is reconstituted and re-weighted semi-annually. Modified capitalization weighting seeks to weight constituents primarily based on market capitalization, but subject to caps on the weights of the individual securities. During each rebalance, the maximum weight of a company is capped at 8%, the aggregate weight of companies with a weight greater than or equal to 5% is capped at 40%, all remaining companies are capped at a weight of 4.5%, and all constituents are subject to a minimum weight of 0.3%. Generally speaking, this approach will limit the amount of concentration in the largest market capitalization companies and increase company-level diversification. The Underlying Index may include large-, mid- or small-capitalization companies, and components primarily include health care companies. As of January 31, 2023, the Underlying Index had 26 constituents. The Fund's investment objective and Underlying Index may be changed without shareholder approval.
The Underlying Index is sponsored by the Index Provider, which is an organization that is independent of, and unaffiliated with, the Fund and Global X Management Company LLC, the investment adviser for the Fund ("Adviser"). The Index Provider determines the relative weightings of the securities in the Underlying Index and publishes information regarding the market value of the Underlying Index.
The Adviser uses a "passive" or indexing approach to try to achieve the Fund's investment objective. Unlike many investment companies, the Fund does not try to outperform the Underlying Index and does not seek temporary defensive positions when markets decline or appear overvalued.
The Fund generally will use a replication strategy. A replication strategy is an indexing strategy that involves investing in the securities of the Underlying Index in approximately the same proportions as in the Underlying Index. However, the Fund may utilize a representative sampling strategy with respect to the Underlying Index when a replication strategy might be detrimental or disadvantageous to shareholders, such as when there are practical difficulties or substantial costs involved in compiling a portfolio of equity securities to replicate the Underlying Index, in instances in which a security in the Underlying Index becomes temporarily illiquid, unavailable or less liquid, or as a result of legal restrictions or limitations (such as tax diversification requirements) that apply to the Fund but not the Underlying Index.
The Adviser expects that, over time, the correlation between the Fund's performance and that of the Underlying Index, before fees and expenses, will exceed 95%. A correlation percentage of 100% would indicate perfect correlation. If the Fund uses a replication strategy, it can be expected to have greater correlation to the Underlying Index than if it uses a representative sampling strategy.
The Fund concentrates its investments (i.e., holds 25% or more of its total assets) in a particular industry or group of industries to approximately the same extent that the Underlying Index is concentrated. As of January 31, 2023, the Underlying Index was concentrated in the Underlying Index was concentrated in the biotechnology industry and had significant exposure to the health care sector.
CHB - Performance
Return Ranking - Trailing
| Period | CHB Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | -18.0% | -18.0% | 4.5% | 100.00% |
| 1 Yr | -30.3% | -33.8% | 19.6% | 95.15% |
| 3 Yr | -26.9%* | -32.0% | 2.9% | 84.04% |
| 5 Yr | N/A* | -15.8% | 14.4% | 35.48% |
| 10 Yr | N/A* | -4.6% | 9.2% | 66.67% |
* Annualized
Return Ranking - Calendar
| Period | CHB Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2023 | -14.0% | -26.6% | 26.3% | 24.27% |
| 2022 | -33.4% | -41.6% | -9.4% | 90.63% |
| 2021 | -13.5% | -52.5% | 26.5% | 40.86% |
| 2020 | N/A | 1.3% | 138.5% | N/A |
| 2019 | N/A | -1.9% | 42.6% | N/A |
Total Return Ranking - Trailing
| Period | CHB Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | -18.0% | -18.0% | 4.5% | 100.00% |
| 1 Yr | -30.3% | -33.8% | 19.6% | 95.15% |
| 3 Yr | -26.9%* | -32.0% | 2.9% | 84.04% |
| 5 Yr | N/A* | -15.8% | 14.4% | N/A |
| 10 Yr | N/A* | -4.6% | 9.2% | N/A |
* Annualized
Total Return Ranking - Calendar
| Period | CHB Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2023 | -13.6% | -25.7% | 30.1% | 37.86% |
| 2022 | -33.3% | -40.4% | -6.8% | 94.79% |
| 2021 | -13.5% | -48.9% | 29.5% | 59.14% |
| 2020 | N/A | 2.0% | 138.5% | N/A |
| 2019 | N/A | 7.8% | 44.4% | N/A |
CHB - Holdings
Concentration Analysis
| CHB | Category Low | Category High | CHB % Rank | |
|---|---|---|---|---|
| Net Assets | 2.05 M | 1.13 M | 6.93 B | 96.12% |
| Number of Holdings | 44 | 26 | 1189 | 77.00% |
| Net Assets in Top 10 | 1.4 M | 534 K | 3.45 B | 91.00% |
| Weighting of Top 10 | 61.01% | 0.4% | 81.8% | 6.00% |
Top 10 Holdings
- CHONGQING ZHIFEI BIOLOGICA-A COMMON STOCK 8.53%
- CSPC PHARMACEUTICAL GROUP LT COMMON STOCK 8.34%
- CHANGCHUN HIGH NEW TECH-A COMMON STOCK 8.31%
- WUXI BIOLOGICS CAYMAN INC COMMON STOCK 6.75%
- WALVAX BIOTECHNOLOGY CO-A COMMON STOCK 6.26%
- BEIJING TIANTAN BIOLOGICAL-A COMMON STOCK 4.92%
- SHANGHAI RAAS BLOOD PRODUC-A COMMON STOCK 4.91%
- SICHUAN KELUN PHARMACEUTIC-A COMMON STOCK 4.51%
- HUALAN BIOLOGICAL ENGINEER-A COMMON STOCK 4.32%
- GENSCRIPT BIOTECH CORP COMMON STOCK 4.17%
Asset Allocation
| Weighting | Return Low | Return High | CHB % Rank | |
|---|---|---|---|---|
| Stocks | 99.96% | 0.00% | 101.98% | 10.89% |
| Cash | 0.04% | 0.00% | 99.01% | 95.00% |
| Preferred Stocks | 0.00% | 0.00% | 2.60% | 86.00% |
| Other | 0.00% | -0.02% | 47.32% | 80.00% |
| Convertible Bonds | 0.00% | 0.00% | 0.15% | 85.86% |
| Bonds | 0.00% | 0.00% | 69.90% | 86.14% |
Stock Sector Breakdown
| Weighting | Return Low | Return High | CHB % Rank | |
|---|---|---|---|---|
| Healthcare | 95.49% | 0.00% | 100.00% | 2.02% |
| Consumer Defense | 4.51% | 0.00% | 20.13% | 79.80% |
| Utilities | 0.00% | 0.00% | 11.37% | 91.92% |
| Technology | 0.00% | 0.00% | 58.02% | 100.00% |
| Real Estate | 0.00% | 0.00% | 22.12% | 95.96% |
| Industrials | 0.00% | 0.00% | 36.69% | 100.00% |
| Financial Services | 0.00% | 0.00% | 41.62% | 100.00% |
| Energy | 0.00% | 0.00% | 19.38% | 90.91% |
| Communication Services | 0.00% | 0.00% | 41.06% | 97.98% |
| Consumer Cyclical | 0.00% | 0.00% | 95.37% | 100.00% |
| Basic Materials | 0.00% | 0.00% | 19.86% | 97.98% |
Stock Geographic Breakdown
| Weighting | Return Low | Return High | CHB % Rank | |
|---|---|---|---|---|
| Non US | 96.21% | 0.00% | 99.76% | 24.00% |
| US | 3.76% | 0.00% | 99.93% | 59.00% |
CHB - Expenses
Operational Fees
| CHB Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Expense Ratio | 0.65% | 0.09% | 12.20% | 88.00% |
| Management Fee | 0.65% | 0.09% | 1.50% | 17.48% |
| 12b-1 Fee | N/A | 0.00% | 1.00% | 48.28% |
| Administrative Fee | N/A | 0.06% | 0.25% | N/A |
Sales Fees
| CHB Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Front Load | N/A | 3.50% | 5.75% | N/A |
| Deferred Load | N/A | 1.00% | 1.00% | N/A |
Trading Fees
| CHB Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Max Redemption Fee | N/A | 2.00% | 2.00% | N/A |
Related Fees
Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.
| CHB Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Turnover | N/A | 4.00% | 241.00% | N/A |
CHB - Distributions
Dividend Yield Analysis
| CHB | Category Low | Category High | CHB % Rank | |
|---|---|---|---|---|
| Dividend Yield | 0.11% | 0.00% | 5.64% | 24.27% |
Dividend Distribution Analysis
| CHB | Category Low | Category High | Category Mod | |
|---|---|---|---|---|
| Dividend Distribution Frequency | SemiAnnual | Annual | Annual | Annual |
Net Income Ratio Analysis
| CHB | Category Low | Category High | CHB % Rank | |
|---|---|---|---|---|
| Net Income Ratio | -0.31% | -1.76% | 3.66% | 70.71% |
Capital Gain Distribution Analysis
| CHB | Category Low | Category High | Capital Mode | |
|---|---|---|---|---|
| Capital Gain Distribution Frequency | Annually | Semi-Annually | Annually |
Distributions History
| Date | Amount | Type |
|---|---|---|
| Jan 08, 2024 | $0.002 | OrdinaryDividend |
| Jul 10, 2023 | $0.037 | OrdinaryDividend |
CHB - Fund Manager Analysis
Managers
Nam To
Start Date
Tenure
Tenure Rank
Sep 22, 2020
1.69
1.7%
Nam To, CFA, joined Global X Management Company LLC in July 2017 as a Portfolio Management Analyst. Mr. To has been a Portfolio Manager of the Fund since March 1, 2018. Previously, Mr. To was a Global Economics Research Analyst at Bunge Limited from 2014 through 2017 and an Advisory and Investment Analyst at Horizon Capital Group from June 2013 through August 2013. Mr. To received his Bachelor of Arts in Philosophy and Economics from Cornell University in 2014.
Wayne Xie
Start Date
Tenure
Tenure Rank
Sep 22, 2020
1.69
1.7%
Wayne Xie joined the Global X Management Company LLC in July 2018 as a Portfolio Management Associate. Previously, Mr. Xie was an Analyst at VanEck Associates on the Equity ETF Investment Management team from 2010 to 2018 and a Portfolio Administrator at VanEck Associates from 2007 to 2010. Mr. Xie received his BS in Business Administration from State University of New York at Buffalo.
Kimberly Chan
Start Date
Tenure
Tenure Rank
Sep 22, 2020
1.69
1.7%
Kimberly Chan is a Portfolio Management Associate. Previously, Ms. Chan was a US Associate Trader at Credit Agricole from 2016 to 2018, and an Investment Analyst at MetLife Investments from 2015 to 2016. Ms. Chan received her Bachelor of Science from New York University in 2015.
Vanessa Yang
Start Date
Tenure
Tenure Rank
Dec 31, 2020
1.41
1.4%
Vanessa Yang, Portfolio Management Associate, joined Global X Management Company LLC in 2016 as a Portfolio Administrator. She was appointed to the portfolio management team in June 2019. Previously, Ms. Yang was a Portfolio Administrator at VanEck Associates from 2011 to 2014. Ms. Yang received her MS in Financial Engineering from Drucker School of Management in 2010 and her BS in Economics from Guangdong University of Foreign Studies in 2008.
William Helm
Start Date
Tenure
Tenure Rank
Apr 01, 2022
0.16
0.2%
William Helm, CFA, Portfolio Manager, joined the Adviser in September 2021. Previously, Mr. Helm spent 14 years at Vanguard where he most recently served as an Equity Portfolio Manager and Trader. Previously, he held roles in Portfolio Review, Corporate Strategy and Corporate Finance. Mr. Helm received his BBA in Economics from Belmont University in 2007 and his MBA from Columbia Business School in 2020.
Sandy Lu
Start Date
Tenure
Tenure Rank
Apr 01, 2022
0.16
0.2%
Sandy Lu, CFA, Portfolio Manager, joined the Adviser in September 2021. Previously, Mr. Lu worked at PGIM Fixed Income from 2014 to 2021, where he led the portfolio analyst team covering Emerging Markets Debt. He began his career in 2010 as an Investment Analyst at Lincoln Financial Group. Mr. Lu graduated with a B.S. in Economics from the Wharton School of the University of Pennsylvania. He earned his CFA designation in September 2015, and holds the Series 3 license.
Tenure Analysis
| Category Low | Category High | Category Average | Category Mode |
|---|---|---|---|
| 0.09 | 24.1 | 3.67 | 3.22 |
